Resultados de búsqueda - Vladimir Janković

  • Mostrando 1 - 14 Resultados de 14
Limitar resultados
  1. 1
    Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells

    Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells por Vladimir Janković, Alessia Ciarrocchi, Piernicola Boccuni, Tony DeBlasio, Robert Benezra, Stephen D. Nimer

    Publicado 2007
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  2. 2
    Id1 Restrains p21 Expression to Control Endothelial Progenitor Cell Formation

    Id1 Restrains p21 Expression to Control Endothelial Progenitor Cell Formation por Alessia Ciarrocchi, Vladimir Janković, Yuval Shaked, Daniel J. Nolan, Vivek Mittal, Robert S. Kerbel, Stephen D. Nimer, Robert Benezra

    Publicado 2007
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7

    Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7 por Benjamin J. Thompson, Vladimir Janković, Jie Gao, Silvia Buonamici, Alan Vest, Jennifer May Lee, Jiří Zavadil, Stephen D. Nimer, Iannis Aifantis

    Publicado 2008
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    Hedgehog Signaling Is Dispensable for Adult Hematopoietic Stem Cell Function

    Hedgehog Signaling Is Dispensable for Adult Hematopoietic Stem Cell Function por Jie Gao, Stephanie Graves, Ute Koch, Suqing Liu, Vladimir Janković, Silvia Buonamici, Abdeljabar El Andaloussi, Stephen D. Nimer, Barbara L. Kee, Russell S. Taichman, Freddy Radtke, Iannis Aifantis

    Publicado 2009
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity

    Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity por Xinyang Zhao, Vladimir Janković, Alexander Gural, Gang Huang, Animesh Pardanani, Sílvia Menéndez, Jin Zhang, Richard F. Dunne, Andrew Xiao, Hediye Erdjument‐Bromage, C. David Allis, Paul Tempst, Stephen D. Nimer

    Publicado 2008
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Human placenta‐derived adherent cells induce tolerogenic immune responses

    Human placenta‐derived adherent cells induce tolerogenic immune responses por Wei Liu, Andrew Morschauser, Xin Zhang, Xiaohua Lu, Joseph Gleason, Shuyang He, Hong‐Jung Chen, Vladimir Janković, Qian Ye, Kristen Labazzo, Uri Herzberg, Vivian R. Albert, Stewart Abbot, Bitao Liang, Robert Hariri

    Publicado 2014
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

    Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractor... por Jurriaan Brouwer‐Visser, Nathalie Fiaschi, Raquel P. Deering, Kamil J. Cygan, Darius Scott, Se Jeong, Lauren Boucher, Namita Gupta, Suraj Gupta, Christina Adler, Max S. Topp, Rajat Bannerji, Johannes Duell, Ranjana H. Advani, Dina M. Flink, Aafia Chaudhry, Gavin Thurston, Srikanth R. Ambati, Vladimir Janković

    Publicado 2024
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 <sup>+</sup> T cell dysfunction and maintain memory phenotype

    Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 <sup>+</sup> T cell dysfunction and maintain memory phenotype por Bei Wang, Wen Zhang, Vladimir Janković, Jacquelynn Golubov, Patrick Poon, Erin Oswald, Cagan Gurer, Joyce Wei, Ilyssa Ramos, Qi Wu, Janelle Waite, Min Ni, Christina Adler, Yi Wei, Lynn E. Macdonald, Tracey Rowlands, Susannah Brydges, Jean Siao, William Poueymirou, Douglas MacDonald, George D. Yancopoulos, Matthew A. Sleeman, Andrew Murphy, Dimitris Skokos

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

    Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial por Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang, Karl D. Lewis, Chrysalyne D. Schmults, Leonel F. Hernandez‐Aya, Friedegund Meier, Dirk Schadendorf, Alexander Guminski, Axel Hauschild, Deborah Jean Lee Wong, Gregory A. Daniels, Carola Berking, Vladimir Janković, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Matthew G. Fury, Danny Rischin

    Publicado 2020
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

    Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing por Danny Rischin, Michael R. Migden, Annette M. Lim, Chrysalyne D. Schmults, Nikhil I. Khushalani, Brett Hughes, Dirk Schadendorf, Lara Dunn, Leonel F. Hernandez‐Aya, Anne Lynn S. Chang, Badri Modi, Axel Hauschild, Claas Ulrich, Thomas Eigentler, B. Stein, Anna C. Pavlick, J.L. Geiger, Ralf Gutzmer, Murad Alam, Emmanuel Chiebuka Okoye, Melissa Mathias, Vladimir Janković, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, Israel Lowy, Matthew G. Fury, Alexander Guminski

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma

    Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma por Omid Hamid, Karl D. Lewis, Amy Weise, Meredith McKean, Kyriakos P. Papadopoulos, John Crown, Tae Min Kim, Dae Ho Lee, Sajeve Thomas, Janice M. Mehnert, John M. Kaczmar, Nehal J. Lakhani, Kevin B. Kim, Mark R. Middleton, Guilherme Rabinowits, Alexander I. Spira, Melinda Yushak, Inderjit Mehmi, Fang Fang, Shuquan Chen, Jayakumar Mani, Vladimir Janković, Fang Wang, Nathalie Fiaschi, Laura K. Brennan, Anne Paccaly, Sheila Masinde, Mark Salvati, Matthew G. Fury, Glenn S. Kroog, Israel Lowy, Giuseppe Gullo

    Publicado 2024
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Survival with Cemiplimab in Recurrent Cervical Cancer

    Survival with Cemiplimab in Recurrent Cervical Cancer por Krishnansu S. Tewari, Bradley J. Monk, Ignace Vergote, Austin Miller, Andréia Cristina de Melo, Hee‐Seung Kim, Yong Man Kim, Alla Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih‐Long Chang, Evgeniy A. Gotovkin, Shunji Takahashi, Daniella Ramone, Joanna Pikiel, Beata Maćkowiak-Matejczyk, Eva Maria Guerra Alía, Nicoletta Colombo, Yulia Makarova, Danny Rischin, Stéphanie Lheureux, Kosei Hasegawa, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Vladimir Janković, Chieh-I Chen, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin

    Publicado 2022
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

    Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial por Alexander Stratigos, Aleksandar Sekulić, Ketty Peris, Oliver Bechter, S. Prey, Martin Kaatz, Karl D. Lewis, Nicole Basset‐Séguin, Anne Lynn S. Chang, Stéphane Dalle, Almudena Fernández Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R. Migden, Reinhard Dummer, Siyu Li, Suk-Young Yoo, Kosalai Kal Mohan, Ebony Coates, Vladimir Janković, Nathalie Fiaschi, Emmanuel Chiebuka Okoye, Ioannis D. Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Timothy G. Bowler, Matthew G. Fury

    Publicado 2021
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

    Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial por Thomas U. Marron, Maria Isabel Fiel, Pauline Hamon, Nathalie Fiaschi, Edward Kim, Stephen C. Ward, Zhen Zhao, Joel Kim, Paul Kennedy, Ganesh Gunasekaran, Parissa Tabrizian, Deborah Blythe Doroshow, Meredith Legg, Ashley Hammad, Assaf Magen, Alice O. Kamphorst, Muhammed Shareef, Namita Gupta, Raquel P. Deering, Wei Wang, Fang Wang, Pradeep Thanigaimani, Jayakumar Mani, Leanna Troncoso, Alexandra Tabachnikova, Christie Chang, Güray Aktürk, Mark Buckup, Steven Hamel, Giorgio Ioannou, C. Hennequin, Hajra Jamal, Haley E. Brown, Antoinette Bonaccorso, Daniel M. Labow, Umut Sarpel, Talia D. Rosenbloom, Max W. Sung, Baijun Kou, Siyu Li, Vladimir Janković, Nicola James, Sara Hamon, Hung Kam Cheung, Jennifer S. Sims, Elizabeth Miller, Nina Bhardwaj, Gavin Thurston, Israel Lowy, Sacha Gnjatic, Bachir Taouli, Myron Schwartz, Miriam Mérad

    Publicado 2022
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: